Related Experiment Videos
Binding, internalization and degradation of EGF-dextran conjugates in two human bladder-cancer cell lines
A Sjöström1, P Bue, P U Malmström
1Biomedical Radiation Sciences, Uppsala University, Sweden. Anna.Sjostrom@bms.uu.se
Abstract:
Bladder carcinomas often have an increased number of epidermal growth factor (EGF) receptors. The EGF receptors can, in these cases, be targets for toxic conjugates. In this study, EGF-dextran conjugates were used as targeting agents with therapeutic potential. The binding, internalization and degradation of 125I-EGF-dextran conjugates in J82 and RT4, 2 different bladder cancer cell lines, were investigated. The behaviour of 125I-EGF was studied as a comparison. The 125I-EGF-dextran showed a continuous increase in binding up to 24 hr, while 125I-EGF exhibited maximum binding after about 90 min. Both cell lines showed similar binding patterns. The binding of 125I-EGF-dextran and 125I-EGF was, on both cell lines, receptor-specific since the binding could be displaced with non-radioactive EGF. Analysis of internalized and membrane-bound 125I activity after administration of 125I-EGF-dextran showed that most of the activity was membrane-bound. A large part of both the internalized and the membrane-bound activity remained cell-associated up to 24 hr. The internalized and membrane-bound activity after administration of 125I-EGF decreased rapidly and only a small fraction remained cell-associated after 24 hr. 125I-EGF-dextran remained cell-associated, with only a limited release of low- and high-molecular-weight radioactivity throughout the 24-hr period, while 125I-EGF was extensively degraded and released into the incubation medium as low-molecular-weight radioactivity during this time. Several qualities of the 125I-EGF-dextran conjugates might be favourable for targeted radiotherapy.
Insights
EGF-dextran conjugates show sustained binding and cell association in bladder cancer cells, unlike EGF alone. These properties suggest potential for targeted radiotherapy in bladder carcinomas.
Area of Science:
- Oncology
- Biochemistry
- Radiotherapy
Background:
- Bladder carcinomas frequently exhibit elevated epidermal growth factor (EGF) receptor expression.
- EGF receptors present a potential target for therapeutic conjugates in bladder cancer treatment.
Purpose of the Study:
- To investigate the binding, internalization, and degradation of EGF-dextran conjugates in bladder cancer cell lines.
- To compare the cellular behavior of EGF-dextran conjugates with unconjugated EGF.
Main Methods:
- Utilized radioiodinated EGF-dextran conjugates and EGF (125I-EGF) for binding studies.
- Assessed receptor specificity by employing non-radioactive EGF for displacement assays.
- Quantified internalized and membrane-bound radioactivity over a 24-hour period in J82 and RT4 cell lines.
Main Results:
- EGF-dextran conjugates demonstrated continuous binding over 24 hours, contrasting with EGF's peak binding at 90 minutes.
- Both conjugates and EGF showed receptor-specific binding, inhibitable by non-radioactive EGF.
- EGF-dextran conjugates exhibited prolonged cell association with minimal degradation, while EGF was rapidly degraded and released.
Conclusions:
- EGF-dextran conjugates display favorable characteristics for targeted radiotherapy due to sustained cell association.
- The prolonged retention of EGF-dextran conjugates on cancer cells warrants further investigation for therapeutic applications.
- These findings support the potential of EGF-dextran conjugates as targeted delivery agents in bladder cancer.